New hope for rare eye cancer: IMCgp100 shows promise in advanced uveal melanoma trial
Disease control
Completed
This study tested a new drug called IMCgp100 in 378 adults with a specific genetic type (HLA-A*0201) of advanced uveal melanoma, a rare eye cancer. Participants received either IMCgp100 or one of three standard treatments (dacarbazine, ipilimumab, or pembrolizumab). The main goal…
Phase: PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC